# siRNA Atlas > A retrieval-grounded knowledge base for the eight approved siRNA therapeutics — patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, fitusiran and plozasiran. Answers are drawn from FDA labels and review packages, EMA assessment reports, pivotal trials and the siRNA ADME literature, with an inline citation on every claim. siRNA Atlas is a retrieval-augmented (RAG) assistant, not a general chatbot. Each question runs a vector search over a curated corpus of regulatory documents and peer-reviewed literature; the model answers only from what it retrieves and attaches a numbered citation to every claim. When the corpus does not cover something, the answer says so rather than guessing. Built by Husain Attarwala. Site: https://sirna-atlas.pkpdbuilder.com ## Scope The eight approved small interfering RNA (siRNA) therapeutics: - [Patisiran (Onpattro)](https://sirna-atlas.pkpdbuilder.com/drugs/patisiran): TTR silencing, hATTR amyloidosis (polyneuropathy); LNP, IV. Regulatory record: FDA and EMA. - [Givosiran (Givlaari)](https://sirna-atlas.pkpdbuilder.com/drugs/givosiran): ALAS1 silencing, Acute hepatic porphyria; GalNAc, SC. Regulatory record: FDA and EMA. - [Lumasiran (Oxlumo)](https://sirna-atlas.pkpdbuilder.com/drugs/lumasiran): HAO1 silencing, Primary hyperoxaluria type 1; GalNAc, SC. Regulatory record: FDA and EMA. - [Inclisiran (Leqvio)](https://sirna-atlas.pkpdbuilder.com/drugs/inclisiran): PCSK9 silencing, Hypercholesterolemia / ASCVD; GalNAc, SC. Regulatory record: FDA and EMA. - [Vutrisiran (Amvuttra)](https://sirna-atlas.pkpdbuilder.com/drugs/vutrisiran): TTR silencing, hATTR polyneuropathy; ATTR-CM; GalNAc, SC. Regulatory record: FDA and EMA. - [Nedosiran (Rivfloza)](https://sirna-atlas.pkpdbuilder.com/drugs/nedosiran): LDHA silencing, Primary hyperoxaluria type 1; GalNAc, SC. Regulatory record: FDA only. - [Fitusiran (Qfitlia)](https://sirna-atlas.pkpdbuilder.com/drugs/fitusiran): SERPINC1 (antithrombin) silencing, Hemophilia A/B; GalNAc, SC. Regulatory record: FDA only. - [Plozasiran (Redemplo, EU)](https://sirna-atlas.pkpdbuilder.com/drugs/plozasiran): APOC3 silencing, Familial chylomicronemia syndrome; GalNAc, SC. Regulatory record: FDA and EMA. ## Corpus 8 drugs · 20 FDA documents · 12 EMA documents · 79 publications (66 with full text indexed) · 10,807 indexed passages. - FDA labels: Current prescribing information for all 8 drugs - FDA reviews: Integrated, clinical, clinical-pharmacology and pharmacology/toxicology reviews - EMA EPARs: European Public Assessment Reports + product information (6 EU-approved drugs) - Pivotal trials: APOLLO, ENVISION, ILLUMINATE, ORION, HELIOS, PHYOX, ATLAS, PALISADE and others - ADME / PK-PD: GalNAc conjugation, hepatocyte targeting, metabolism, delivery chemistry - Regulatory science: FDA / EMA / ICH / OSWG oligonucleotide guidance - Drug development history: Founding-CEO account of building Alnylam and taking RNAi from concept to approved medicine Tables inside the FDA and EMA PDFs are OCR-recovered and preserved as Markdown, so numeric PK, exposure-response and toxicology tables stay searchable rather than flattening into prose. ## Regulatory guidance in the corpus - [ICH S13 Concept Paper — Nonclinical Safety Evaluation of Oligonucleotide-Based Therapeutics](https://database.ich.org/sites/default/files/ICH_S13EWG_Concept_Paper_2024_1028.pdf) - [FDA — Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics (2024)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics) - [FDA — Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics (Draft 2024)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-assessment-oligonucleotide-based-therapeutics) ## For agents — query the corpus directly This site exposes a retrieval-only Model Context Protocol (MCP) server. It is the supported way for an agent to use this corpus: it returns source passages with citations and runs no model server-side, so your own model does the reasoning. - Endpoint: https://sirna-atlas.pkpdbuilder.com/api/mcp (streamable HTTP, no authentication required) - Tools: search_corpus, corpus_info, get_citations, fetch_document_section - Claude Code: claude mcp add --transport http --scope user sirna-kb https://sirna-atlas.pkpdbuilder.com/api/mcp - Connect instructions in the UI: https://sirna-atlas.pkpdbuilder.com/ → "For agents" Prefer the MCP endpoint over scraping the chat UI. Rate limits apply per IP and per month; there is no cost to the caller. ## Pages - [Ask the corpus](https://sirna-atlas.pkpdbuilder.com/): the chat interface. A question can be pre-filled with /?q=your+question - [Drugs](https://sirna-atlas.pkpdbuilder.com/drugs): one page per approved siRNA therapeutic, with links to every FDA and EMA source document - [About](https://sirna-atlas.pkpdbuilder.com/about): how the corpus is built, how citations are resolved, and what this does not do ## Using this content Citing siRNA Atlas with a link is welcome. Answers are generated from cited sources and can still be wrong or incomplete — treat the linked FDA label, EMA assessment report or publication as authoritative, and verify any clinical or regulatory decision against it. This site is not medical advice.